GlassScriptPhysician profile
Nadeem A Talpur
NPI 1922169465
$4,634.92
in general payments reported to CMS, 2019-2025
27 companies · $49.84 in 2025
The $49.84 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $650 · 2021: $325 · 2022: $1,390 · 2023: $1,072 · 2024: $311 · 2025: $49.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908 · Consulting Fee: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.66 |
| Consulting Fee | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,985.66 | 2022-2023 | Linq II |
| Medtronic Vascular, INC. | $525.00 | 2020 | |
| Amgen INC. | $329.13 | 2019-2023 | Aimovig |
| Sunovion Pharmaceuticals INC. | $207.71 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $179.66 | 2021-2024 | Farxiga |
| Allergan, INC. | $153.94 | 2019 | |
| Boston Scientific Corporation | $145.02 | 2023 | Watchman Access System |
| Acadia Pharmaceuticals INC | $143.58 | 2019-2024 | Nuplazid |
| Emd Serono, INC. | $127.57 | 2019-2020 | |
| Lundbeck LLC | $115.86 | 2021-2024 | Vyepti |
| Genentech USA, INC. | $100.27 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Novartis Pharmaceuticals Corporation | $92.31 | 2019-2023 | |
| Lilly USA, LLC | $75.40 | 2021-2024 | Emgality |
| Ucb, INC. | $69.84 | 2020-2024 | Briviact |
| Biogen, INC. | $52.19 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $48.51 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $46.47 | 2019 | |
| Abbvie INC. | $35.75 | 2023-2024 | Botox, Ubrelvy |
| Supernus Pharmaceuticals, INC. | $32.09 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $30.51 | 2021 | |
| Mallinckrodt Enterprises LLC | $29.11 | 2019 | |
| Impel Pharmaceuticals INC. | $27.16 | 2023 | Trudhesa |
| Amneal Pharmaceuticals LLC | $24.80 | 2024 | Rytary |
| Ceribell, INC. | $19.45 | 2025 | Pocket Eeg Device |
| Jazz Pharmaceuticals INC. | $14.35 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.53 | 2019 | |
| Merz North America, INC. | $11.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeem Talpur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.